Immunic AG | WebDisclosure

Basculer en Français

10656	Companies
226798	Keywords
155228	Articles
120063	Press releases

Home
Companies
Immunic AG

PRESS RELEASE

published on 02/20/2025 at 13:30, 1 year 4 months ago

Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
Immunic's Oral IMU-856 shows dose-dependent increase of GLP-1 in celiac disease patients, potential as oral weight management treatment. New data presented in webcast

Immunic GLP-1 IMU-856 Celiac Disease Weight Management
BRIEF

published on 02/04/2025 at 12:35, 1 year 4 months ago

Immunic Announces February Participation in Key Conferences

Biotechnology Investor Engagement Immunic Conferences IMU-856 Data IMU-838 Research
BRIEF

published on 02/04/2025 at 12:35, 1 year 4 months ago

Immunic annonce sa participation à des conférences clés en février

Biotechnologie Engagement Des Investisseurs Conférences Immuniques Données IMU-856 Recherche IMU-838
PRESS RELEASE

published on 02/04/2025 at 12:30, 1 year 4 months ago

Immunic to Participate in Investor and Scientific Conferences in February
Immunic, Inc. (Nasdaq: IMUX) to participate in investor and scientific conferences in February, presenting research on IMU-856, IMU-838, and gastrointestinal diseases

Investor Conferences Immunic Inc. Scientific Conferences IMU-856 IMU-838
BRIEF

published on 01/07/2025 at 12:35, 1 year 5 months ago

Immunic's 2024 Achievements and Future Prospects

Clinical Trials Multiple Sclerosis Vidofludimus Calcium 2024 Milestones Immunic AG
BRIEF

published on 01/07/2025 at 12:35, 1 year 5 months ago

Réalisations et perspectives d'avenir d'Immunic en 2024

Essais Cliniques Sclérose En Plaques Immunic SA Vidofludimus Calcique Étapes Clés De 2024
PRESS RELEASE

published on 01/07/2025 at 12:30, 1 year 5 months ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Immunic, Inc. highlights its 2024 accomplishments and upcoming milestones, including positive trial results for vidofludimus calcium in multiple sclerosis. Strengthened team and secured private placement for future growth

Multiple Sclerosis Immunic Vidofludimus Calcium 2024 Accomplishments Upcoming Milestones
BRIEF

published on 11/26/2024 at 12:35, 1 year 7 months ago

Immunic, Inc. Set to Participate in December Investor Conference

Investor Conference Immunic, Inc. Vidofludimus Calcium Piper Sandler Small Molecule Therapies
BRIEF

published on 11/26/2024 at 12:35, 1 year 7 months ago

Immunic, Inc. s'apprête à participer à la conférence des investisseurs de décembre

Immunic, Inc. Conférence Des Investisseurs Vidofludimus Calcique Piper Sandler Thérapies À Base De Petites Molécules
PRESS RELEASE

published on 11/26/2024 at 12:30, 1 year 7 months ago

Immunic, Inc. to Participate in Investor Conference in December
Immunic, Inc. to Participate in Investor Conference in December. Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing therapies for chronic inflammatory and autoimmune diseases, announces participation in Piper Sandler 36th Annual Healthcare Conference in New York

Investor Conference Biotechnology Immunic Inc. Clinical Pipeline Autoimmune Diseases

Accesswire

Published on 06/29/2026 at 15:00, 1 hour 8 minutes ago

Infield Minerals Significantly Expands Land Holdings and Builds Regional Presence at the Detroit Gold Project in Utah
Published on 06/29/2026 at 15:00, 1 hour 8 minutes ago

Vox Royalty Highlights Significant Gold Offtake-Stream Exposure to Los Filos Following Key Milestone Announcement
Published on 06/29/2026 at 14:30, 1 hour 38 minutes ago

Unusual Machines Added to Russell 2000(R) Index
Published on 06/29/2026 at 14:30, 1 hour 38 minutes ago

Sekur Private Data Makes First Intl. Call on SekurOne - Launches SekurOne for Android and Web
Published on 06/29/2026 at 14:30, 1 hour 38 minutes ago

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

View all ACCESSWIRE

EQS Group

Published on 06/29/2026 at 15:34, 33 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/29/2026 at 15:33, 34 minutes ago

Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 06/29/2026 at 15:32, 35 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 06/29/2026 at 15:31, 36 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 06/29/2026 at 15:30, 37 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited

Les Echos

Published on 06/29/2026 at 10:56, 5 hours 12 minutes ago

GUILLEMOT CORPORATION S.A. | Déclaration hebdomadaire des transactions sur actions propres du 22 au 26 juin 2026
Published on 06/29/2026 at 10:56, 5 hours 12 minutes ago

GUILLEMOT CORPORATION S.A. | Weekly report share buyback from June 22 to June 26 2026
Published on 06/26/2026 at 17:45, 2 days 22 hours ago

Combined General Meeting, June 25, 2026
Published on 06/26/2026 at 17:45, 2 days 22 hours ago

Assemblée générale mixte du 25 juin 2026
Published on 06/26/2026 at 17:45, 2 days 22 hours ago

Descriptif du programme de rachat d'actions

View all LES ECHOS COMFI WIRE